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Abstract
Cystic fibrosis (CF) is a common autosomal recessive disease. Life expectancy of
patients with CF continues to improve mainly driven by the evolving therapies
for CF-related organ dysfunction. The prevalence of CF-related diabetes (CFRD)
increases exponentially as patients’ age. Clinical care guidelines for CFRD from
2010, recommend insulin as the mainstay of treatment. Many patients with CFRD
may not require exogenous insulin due to the heterogeneity of this clinical entity.
Maintenance of euglycemia by enhancing endogenous insulin production,
secretion and degradation with novel pharmacological therapies like glucagon-
like peptide-1 agonist is an option that remains to be fully explored. As such, the
scope of this article will focus on our perspective of glucagon-like peptide-1
receptor agonist in the context of CFRD. Other potential options such as sodium-
glucose cotransporter-2 and dipeptidyl peptidase 4 inhibitors and their impact on
this patient population is limited and further studies are required.
Key words: Cystic fibrosis; Cystic fibrosis-related diabetes; Cystic fibrosis transmembrane
conductance regulator; Gastric inhibitory polypeptide; Glucagon-like peptide 1;
Glucagon-like peptide-1 receptor agonist; Dipeptidyl peptidase 4 inhibitors
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Core tip: Cystic fibrosis-related diabetes is a heterogeneous entity. Currently, insulin is
the agent of choice to maintain euglycemia on this patient population. Novel therapies
like glucagon-like peptide-1 agonist offer an opportunity to reevaluate the way we
approach this disease.
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Cystic fibrosis (CF) is a common autosomal recessive disease that has been described
to affect Caucasians and, to a lesser extent, other populations, affecting up to 1 person
per every 3000 live births[1] in the United States. Its pathogenesis is secondary to a
defect in the CF transmembrane conductance regulator (CFTR) gene that encodes for a
homonymous membrane protein that conducts chloride ions across epithelial cell
membranes,  resulting  in  dysregulation  of  the  normal  pH  and  ionic  balance  of
physiologic secretions and subsequent multiorgan dysfunction[2].
Despite  discrepancies  in  the  median  age  at  death  between  different  patient
populations[3], the life expectancy of patients with CF continues to improve mainly
driven by the evolving therapies for CF-related organ dysfunction. However, new
challenges in the form of chronic-degenerative diseases arise from this increased life
expectancy. The prevalence of CF-related diabetes (CFRD) increases exponentially
when patients reach adulthood[4,5].
PATHOPHYSIOLOGY OF CYSTIC FIBROSIS-RELATED
DIABETES
CFRD is a unique disease that combines features of patients with type 1 and type 2
diabetes  mellitus  (T1DM  and  T2DM)  such  as  impaired  insulin  secretion  and
peripheral insulin resistance[6]. Due to the heterogeneity of CF, it is difficult to predict
which patients will go on to develop CFRD. Some mutations, however, have a higher
prevalence  and  predisposition  to  develop  the  disease  and  are  associated  with
pancreatic exocrine dysfunction[7].
CFTR plays a dual role in insulin/glucagon hemostasis. Abnormal intracellular
accumulation of chloride in β cells impairs their ability to depolarize in response to
glucose,  diminishing insulin  release.  In  α  cells,  normal  glucagon suppression is
impaired by the inability of the cells to hyperpolarize in presence of high intracellular
chloride, resulting in uncontrolled secretion of glucagon by potentiating adenosine
triphosphate-sensitive K+ channels[8-10] (Figure 1).
Exocrine pancreatic insufficiency is an independent factor that must be accounted
for. The low bicarbonate to chloride transport ratio, which reduces secretory volume,
creates  a  protein  gradient  at  the  lumen,  resulting  in  obstruction and interstitial
edema[11]. Evidence suggests that, overtime, the resulting histopathological changes
correlate with progression of the disease, damaging islet cells. Furthermore, CFRD
patients have low levels of gastric inhibitory polypeptide (GIP) and glucagon-like
peptide-1 (GLP-1), which contributes to postprandial glycemic excursions and lower
secretion of insulin[12,13].
Insulin resistance is associated with the fluctuant systemic inflammatory process
associated with the counterregulatory response of growth hormone, cortisol  and
catecholamines that are released as a response to frequent pulmonary exacerbations
and their treatment with steroids that these patients are typically exposed to.
THE ROLE OF INCRETINS AND GLUCAGON-LIKE PEPTIDE-1
RECEPTOR AGONIST
The  most  recent  version  of  the  clinical  care  guidelines  for  CFRD  from  2010
recommend insulin as the mainstay of treatment[14]. With the advent of GLP-1 receptor
agonists (GLP-1 RA) this could change in the future for certain subtypes of the disease
in which β cell  structure remains preserved,  but function is  impaired,  similar to
patients with T2DM[15].
GLP-1 RA ameliorate the pathophysiology that has been previously explained (see
above)  by  improving  insulin  release  and  slowing  gastric  emptying,  improving
glycemia[16]. Interestingly, these effects have been reproduced in the past, when GLP-1
RA were not available in the market by using pancreatic enzymes as a replacement of
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Figure 1
Figure 1  Pathophysiology of cystic fibrosis-related diabetes.
the exocrine function of the pancreas[17]. However, approximately 20% of the patients
had refractory disease due to the diminishing bicarbonate levels  secreted by the
pancreas to the intestine, delaying and impairing the effectiveness of fat absorption
while worsening prandial glycemic excursions as a result[18].
Currently, very few studies have been published and even less are underway to
address the use of GLP-1 RA, dipeptidyl peptidase 4 inhibitors or sodium-glucose
cotransporter-2  inhibitors  based therapies  in  the treatment  of  CFRD. One of  the
limitations when designing these studies is the target population. As demonstrated by
Geyer et al[19], exenatide demonstrated to be an effective treatment option for patients
with early-onset CFRD. However, it is important to note this study was done in the
pediatric population,  which is  arguably less affected by CFRD. Another point to
consider is how heterogeneous the patient population can be due to differences in
mutations and residual function of the CFTR protein in individuals that would be
treated with this novel therapy.
One of the issues with GLP-1 RA in this patient population is weight loss, which is
not  desirable  in  this  context.  Classically,  diabetic  patients  must  limit  their
carbohydrate and caloric intake to limit glycemic excursions[5]. This conflicts with the
current recommendations that seek to maintain a good nutritional status with high fat
diets, frequent snacking and weight gain, which is associated with good prognosis[20],
although this is a more important marker for early stages of the disease, which might
not be applicable to CFRD since these patients usually present when they are older
than 18 years of age.
With  the  advent  of  newer,  novel  CFTR  modulating  therapies  such  as
Lumacaftor/Ivacaftor,  attempts  have  been  made  to  determine  if  these  novel
treatments have an impact in CFRD and related conditions[21-23] despite lack of a direct
mechanism of action since β cells do not express CFTR[24]. It has been proposed that
increased levels  of  GLP-1  and GIP with  preservation of  exocrine  and endocrine
pancreatic functions are the main drivers of these positive effects. Large randomized
controlled trials are needed to verify and validate these findings[25], which also go in
favor towards a broader utilization of novel therapies for CFRD.
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CONCLUSION
Many patients with CFRD may not require exogenous insulin despite this being the
approved therapy for all forms of CFRD despite the heterogeneity of CF as a clinical
entity. Maintenance of euglycemia by enhancing endogenous insulin production,
secretion and degradation via improved incretin (GLP-1 and GIP) stabilization and/or
exogenous  administration  might  play  a  central  role  that  is  currently  not  fully
exploited.
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